EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study

Buket Şahin Çelik, Selim Giray Nak

Annals of Clinical and Analytical Medicine · 2026-11-01 · 17 (11) · 1162-1166

DOI: 10.4328/acam.50010 ↗
AbstractBibliografische Angaben

Abstract

Aim Tumor necrosis factor (TNF) plays a pivotal role in the immunopathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate treatment response, treatment-related complications, and clinical outcomes in patients with IBD receiving anti-TNF therapy, specifically infliximab and adalimumab. Methods This retrospective study included 117 patients with IBD who received anti-TNF therapy between January 2012 and May 2017 and were followed at a unıversity gastroenterology department. Treatment responses (complete remission, partial remission, non-response, and death), treatment-related complications, and clinical outcomes were assessed using electronic medical records. Results The median age was 37.5 years (range: 20–77) in patients with Crohn’s disease and 38 years (range: 22–70) in patients with ulcerative colitis (UC). Male predominance was observed in both groups. Infliximab, adalimumab, or both agents were used in 34.0%, 51.1%, and 14.9% of UC patients, and in 45.7%, 34.3%, and 20.0% of Crohn’s disease patients, respectively. The overall response rate to anti-TNF therapy was 69.6%, with response rates of 75.0% in Crohn’s disease and 61.7% in UC. No significant differences were observed between infliximab and adalimumab or between monotherapy and combination therapy. Conclusion Anti-TNF therapy was effective and well-tolerated in both Crohn’s disease and ulcerative colitis. Treatment response was independent of demographic and disease-related factors, while secondary non-response was more common than primary non-response.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →